ArticleNature2021
Cross-HLA targeting of intracellular oncoproteins with peptide-centric CARs.
RetractedOpen access · hybridAbstract readRetracted Publication
In one paragraph
Article in Nature, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 62 papers.
0numbers the graph read from it
0cells of the map it votes in
62citing papers in PubMed
8.4field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
62 citing papers in PubMed, 100 citations in OpenAlex.
- Checkpoint inhibition and beyond: Precision immune engineering for the immune-privileged landscape of ocular malignancies.BioImpacts : BI · 2026Review
- ATLAS-seq: a microfluidic single-cell TCR screen for antigen-reactive TCRs.Nature communications · 2025Article
- Engaging T cells for cleanup.Frontiers in immunology · 2025Review
- Advancement Opportunities and Endeavor of Innovative Targeted Therapies for Small Cell Lung Cancer.International journal of biological sciences · 2025Review
- Bispecific immunotherapy based on antibodies, T-cell receptors, and aptamers: mechanisms of action, adverse effects, and future perspectives.Frontiers in immunology · 2025Review
- CAR-T cells based on a TCR mimic nanobody targeting HPV16 E6 exhibit antitumor activity against cervical cancer.Molecular therapy. Oncology · 2024Article
- MHC-I-presented non-canonical antigens expand the cancer immunotherapy targets in acute myeloid leukemia.Scientific data · 2024Article
- Discovery of immunotherapy targets for pediatric solid and brain tumors by exon-level expression.Nature communications · 2024Article
- Targeting solid tumor antigens with chimeric receptors: cancer biology meets synthetic immunology.Trends in cancer · 2024Review
- Preclinical evaluation of a novel CAR-T therapy utilizing a scFv antibody highly specific to MAGE-A4Molecular therapy : the journal of the American Society of Gene Therapy · 2024Article
- Rationally designed approaches to augment CAR-T therapy for solid tumor treatment.Bioactive materials · 2024Article
- Discovery of immunotherapy targets for pediatric solid and brain tumors by exon-level expression.Research square · 2024Article
- Breast cancer immunopeptidomes contain numerous shared tumor antigens.The Journal of clinical investigation · 2024Article
- Conformational plasticity of RAS Q61 family of neoepitopes results in distinct features for targeted recognition.Nature communications · 2023Article
- Structural principles of peptide-centric chimeric antigen receptor recognition guide therapeutic expansion.Science immunology · 2023Article
- T cell receptor therapeutics: immunological targeting of the intracellular cancer proteome.Nature reviews. Drug discovery · 2023Review
- Next-generation chimeric antigen receptors for T- and natural killer-cell therapies against cancer.Immunological reviews · 2023Review
- Adoptive cell therapy in paediatric extracranial solid tumours: current approaches and future challenges.European journal of cancer (Oxford, England : 1990) · 2023Review
- HLA3DB: comprehensive annotation of peptide/HLA complexes enables blind structure prediction of T cell epitopes.Nature communications · 2023Article
- Exploiting frequent and specific expression of PRL3 in pediatric solid tumors for first-in-child use of PRL3-zumab humanized antibody.Molecular therapy oncolytics · 2023Article
2 more citing papers are in PubMed but not listed here.
Corrections and comments
- Retraction · 2023-11-08Contamination of Materials · Error in Data · Error in Results and/or Conclusions · Retract and Replace ·
- Commented on by
- Commented on by
- Retracted
Authors and funding
28 authors at 5 institutions in 2 countries.
Mark YarmarkovichDivision of Oncology and Center for Childhood Cancer Research, Children's Hospital of Philadelphia, Philadelphia, PA, USA.
Quinlen F MarshallDivision of Oncology and Center for Childhood Cancer Research, Children's Hospital of Philadelphia, Philadelphia, PA, USA.ORCID http://orcid.org/0000-0002-4736-9716
John M WarringtonDivision of Oncology and Center for Childhood Cancer Research, Children's Hospital of Philadelphia, Philadelphia, PA, USA.
Rasika PremaratneMyrio Tx, Melbourne, Victoria, Australia.
Alvin FarrelDivision of Oncology and Center for Childhood Cancer Research, Children's Hospital of Philadelphia, Philadelphia, PA, USA.
David GroffDivision of Oncology and Center for Childhood Cancer Research, Children's Hospital of Philadelphia, Philadelphia, PA, USA.
Wei LiUniversity of Pittsburgh, Pittsburgh, PA, USA.
Moreno di MarcoUniversity of Tubingen, Tubingen, Germany.
Erin RunbeckDivision of Oncology and Center for Childhood Cancer Research, Children's Hospital of Philadelphia, Philadelphia, PA, USA.
Hau TruongDivision of Oncology and Center for Childhood Cancer Research, Children's Hospital of Philadelphia, Philadelphia, PA, USA.
Jugmohit S ToorDepartment of Chemistry and Biochemistry, University of California Santa Cruz, Santa Cruz, CA, USA.
Sarvind TripathiDepartment of Chemistry and Biochemistry, University of California Santa Cruz, Santa Cruz, CA, USA.ORCID http://orcid.org/0000-0002-6959-0577
Son NguyenMassachusetts Institute of Technology, Cambridge, MA, USA.ORCID http://orcid.org/0000-0002-0475-5158
Helena ShenDivision of Oncology and Center for Childhood Cancer Research, Children's Hospital of Philadelphia, Philadelphia, PA, USA.ORCID http://orcid.org/0000-0002-0500-441X
Tiffany NoelDivision of Oncology and Center for Childhood Cancer Research, Children's Hospital of Philadelphia, Philadelphia, PA, USA.
Nicole L ChurchMyrio Tx, Melbourne, Victoria, Australia.
Amber WeinerDivision of Oncology and Center for Childhood Cancer Research, Children's Hospital of Philadelphia, Philadelphia, PA, USA.
Nathan KendserskyDivision of Oncology and Center for Childhood Cancer Research, Children's Hospital of Philadelphia, Philadelphia, PA, USA.ORCID http://orcid.org/0000-0003-0132-8748
Dan MartinezDepartment of Pathology and Lab Medicine, Children's Hospital of Philadelphia, Philadelphia, PA, USA.
Rebecca WeisbergDivision of Oncology and Center for Childhood Cancer Research, Children's Hospital of Philadelphia, Philadelphia, PA, USA.
Molly ChristieDivision of Oncology and Center for Childhood Cancer Research, Children's Hospital of Philadelphia, Philadelphia, PA, USA.
Laurence EisenlohrDepartment of Pathology and Lab Medicine, Children's Hospital of Philadelphia, Philadelphia, PA, USA.
Kristopher R BosseDivision of Oncology and Center for Childhood Cancer Research, Children's Hospital of Philadelphia, Philadelphia, PA, USA.
Dimiter S DimitrovUniversity of Pittsburgh, Pittsburgh, PA, USA.ORCID http://orcid.org/0000-0002-2258-1024
Stefan StevanovicUniversity of Tubingen, Tubingen, Germany.
Nikolaos G SgourakisDivision of Oncology and Center for Childhood Cancer Research, Children's Hospital of Philadelphia, Philadelphia, PA, USA.
Ben R KiefelMyrio Tx, Melbourne, Victoria, Australia.
John M MarisDivision of Oncology and Center for Childhood Cancer Research, Children's Hospital of Philadelphia, Philadelphia, PA, USA. maris@chop.edu.ORCID http://orcid.org/0000-0002-8088-7929
Children's Hospital of Philadelphia · USUniversity of California, Santa Cruz · USUniversity of Pittsburgh · USUniversity of Tübingen · DEMassachusetts Institute of Technology · US
Funding
IMMUNOBIOLOGY OF NORMAL AND NEOPLASTIC LYMPHOCYTEST32CA009140 · NCI · UNIVERSITY OF PENNSYLVANIA · PI Malay Haldar, WARREN S PEAR · 1985 to 2026
$16.1MUnderstanding and Overcoming Resistance to Immunotherapies in Childhood CancersU54CA232568 · NCI · CHILDREN'S HOSP OF PHILADELPHIA · PI MACKALL, CRYSTAL, MARIS, JOHN M · 2018 to 2022
$13.1MDiscovering mechanisms of neuroblastoma tumorigenesis to improve patient outcomesR35CA220500 · NCI · CHILDREN'S HOSP OF PHILADELPHIA · PI JOHN M MARIS · 2017 to 2026
$8.7MAn integrative structural biology approach to understanding metabolite recognition by cellular receptorsR35GM125034 · NIGMS · UNIVERSITY OF CALIFORNIA SANTA CRUZ · PI SGOURAKIS, NIKOLAOS · 2017 to 2025
$4.7MMolecular mechanism of antigen editing by Class-I MHC ChaperonesR01AI143997 · NIAID · UNIVERSITY OF CALIFORNIA SANTA CRUZ · PI SGOURAKIS, NIKOLAOS · 2019 to 2023
$4.0MTargeting the GPC2 oncoprotein with immune-based therapies in neuroblastomaK08CA230223 · NCI · CHILDREN'S HOSP OF PHILADELPHIA · PI BOSSE, KRISTOPHER R · 2018 to 2022
$1.0MNCI NIH HHS K08 CA230223NCI NIH HHS R35 CA220500NCI NIH HHS T32 CA009140NCI NIH HHS U54 CA232568NIAID NIH HHS R01 AI143997NIGMS NIH HHS R35 GM125034
Abstract
The majority of oncogenic drivers are intracellular proteins, thus constraining their immunotherapeutic targeting to mutated peptides (neoantigens) presented by individual human leukocyte antigen (HLA) allotypes
Indexed as
ImmunotherapyAnimalsAntigens, NeoplasmCell LineCell Line, TumorCross-PrimingCross ReactionsFemaleHLA AntigensHomeodomain ProteinsHumansInterferon-gammaMiceNeoplasmsOncogene ProteinsReceptors, Chimeric AntigenAntigens, NeoplasmHLA AntigensHomeodomain ProteinsInterferon-gammaNBPhox proteinOncogene ProteinsReceptors, Chimeric AntigenTranscription Factors
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.